| Toggle Summary
|
Pro-Pharmaceuticals Reports Third Quarter Financial Results
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE
|
View HTML
|
| Toggle Summary
|
THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES
Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells and Removes Their Ability to Evade the Immune System
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM
Studies Demonstrate DAVANAT® Binds To Galectin-1 and Galectin-3 Receptors That Control Angiogenesis and the Tumor's Ability To Evade the Immune System
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS
|
View HTML
|
| Toggle Summary
|
COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND
|
View HTML
|
